{"nctId":"NCT02153528","briefTitle":"Optimization of the TB Treatment Regimen Cascade","startDateStruct":{"date":"2014-11"},"conditions":["Tuberculosis, Pulmonary"],"count":701,"armGroups":[{"label":"Standard TB treatment","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Standard TB treatment"]},{"label":"double rimfampicin","type":"EXPERIMENTAL","interventionNames":["Drug: double rimfampicin"]}],"interventions":[{"name":"double rimfampicin","otherNames":["Intervention arm"]},{"name":"Standard TB treatment","otherNames":["Control arm"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosed with smear-positive pulmonary TB\n* 15 years or older\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* contacts of MDR-TB patients and other MDR-TB suspects diagnosed with resistance on rapid DST for rifampicin performed prior to start of treatment according to NTP guidelines\n* smear-negative pulmonary and extra-pulmonary TB cases\n* patients in need of hospitalization because of very bad general condition or complications\n* patients with clinically active liver disease, for the study defined as jaundice confirmed by a local Medical Officer (Government)\n* any known HIV-positive patient (although none are expected)\n* any patient with known hepatitis B or C infection\n* pregnant women; in addition, patients in the intervention arm who become pregnant during treatment will be switched to the control arm","healthyVolunteers":false,"sex":"ALL","minimumAge":"15 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Tuberculose Treatment Outcome","description":"Following current WHO guidelines, an adverse treatment outcome is defined as any occurrence of the following:\n\n* Relapse: Cured previously from TB or completed treatment for TB and now having bacteriologically positive sputum for TB (at 12 months follow-up or at an earlier time point)\n* Default: The patient whose treatment was interrupted for â‰¥ 2 consecutive months.\n* Failure: Sputum positive for TB at 5 months or later during treatment. In line with current WHO recommendations, patients detected with MDR-TB or rifampicin resistance before this or another outcome applies and switched to the MDR-TB regimen will be excluded from the outcome analysis.18 Failure will also be declared if the regimen has to be changed for at least 2 drugs due to adverse events.\n* Death: All-cause mortality between case registration and end of TB treatment (related or not to TB or TB treatment)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"8","spread":null}]},{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"5","spread":null}]},{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"12","spread":null}]},{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"3","spread":null}]},{"measurements":[{"groupId":"OG000","value":"310","spread":null},{"groupId":"OG001","value":"319","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Who Develop Liver Toxicity","description":"Grade 3-4 Liver Toxicity following NIH common toxicity criteria (CTC), including transaminase increases to \\>5-20 ULN (grade 3), or \\> 20 ULN (grade 4)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"High-level Rifampicin Resistant TB Adverse Treatment Outcomes","description":"To assess whether the study regimen also cures high-level rifampicin resistant TB. Adverse treatment outcomes will be described and compared among treatment groups in subgroups defined by initial rifampicin resistance mutations (performed in all patients) detected.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"40","spread":null}]},{"measurements":[{"groupId":"OG000","value":"281","spread":null},{"groupId":"OG001","value":"290","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Initial Resistant TB Cases Who Switched to MDR-TB Treatment or Were Cured","description":"To assess the effectiveness of FDA vital staining versus fever screening for early switch of non-responding rifampicin resistant TB to MDR-TB treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"the Negative Predictive Value of Conversion at 2 Weeks for Relapse.","description":"The Negative Predictive value (and 95% CI) of conversion in the intervention arm will be estimated as the % of relapses among those with a minimum 1 log decline in the number of AFB, or who are already negative or only scanty positive on AFB smear (auramine or FDA).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Acquired Rifampicin Resistance Among Failures and Relapses","description":"number of failure / relapse cases without mutation detected at diagnosis as the denominator and comparing intervention and control arms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Area Under the Curve of Auramine Resp. FDA at 2 Weeks to Predict Adverse Treatment Outcome at 1 Year After Treatment Completion","description":"Area under the ROC curve (AUC) to predict adverse treatment outcome. The X-axis represents the 1-specificity, the Y-axis represents sensitivity. The AUC is estimated with 95% confidence interval.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.52","spread":null},{"groupId":"OG001","value":"0.54","spread":null}]}]}]},{"type":"SECONDARY","title":"Weight Gain","description":"Weight gain from baseline until end-of-treatment comparison between both treatment arms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.93","spread":"2.44"},{"groupId":"OG001","value":"2.79","spread":"2.44"}]}]}]},{"type":"SECONDARY","title":"Fever Resolution","description":"Comparison of fever resolution after 2 weeks of treatment between both treatment arms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"71","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":24,"n":348},"commonTop":[]}}}